Skip to content

Prospective Randomized Controlled Clinical Study for Lung Health Beverage in Preventing Radiotherapy-Related Lung Diseases in Locally Advanced Esophageal Cancer

Prospective Randomized Controlled Clinical Study for Lung Health Beverage in Preventing Radiotherapy-Related Lung Diseases in Locally Advanced Esophageal Cancer

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033285
Enrollment
Unknown
Registered
2020-05-26
Start date
2020-06-01
Completion date
Unknown
Last updated
2020-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

Sponsors

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. pathological confirmed of esophageal squamous cell carcinoma; 2. TNM stage T3-4N0M0, TxN1-2M0, TxNxM1a (cervical lymph node metastasis); 3. Patients with expected survival >=6 months; 4. Patients aged 18 to 80 years; 5. Patients with ECOG 0-1; 6. Patients with sufficient main organ function (1) Hemopoietic function: hemoglobin >= 100g/L, platelet >= 90 x 10^9/L, neutrophil >= 1.5x10^9/L; (2) Renal function: serum creatinine SCR < 1.5 ULN; (3) Liver function: ALT and AST < ULN one point five Times, bilirubin <1.5 x ULN; 7. The patient must sign the informed consent of receiving concurrent radiotherapy and chemotherapy.

Exclusion criteria

Exclusion criteria: 1. Patients who have previously suffered from or complicated with other malignant tumors (except melanoma skin tumors) and whose diseases are not controlled or cured (depending on the disease type of the primary tumor); 2. Patients who have previously treated with thoracic radiotherapy; 3. Patients with congenital or acquired immune deficiency; 4. HIV positive patients, including those who have received antiretroviral therapy; chronic hepatitis B, virus replication period; active period of hepatitis C; 5. Pregnancy (confirmed by serum or urine beta- hCG test) or lactation period; 6. The general condition of the patients was poor, KPS < 70; 7. Patients have conditions that researchers believe may increase the risk of treatment or have serious uncontrollable complications.

Design outcomes

Primary

MeasureTime frame
acute radiation-induced lung disease;

Secondary

MeasureTime frame
late radiation-induced lung disease;overall survival;overall survival;

Countries

China

Contacts

Public ContactZhao Shengguang

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine

zhaoshengguang@163.com+86 021-64370045

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026